Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Morgan Stanley says Merck is positioned to gain share as its pipeline drugs near commercialization, supporting a more favorable near-term outlook. The catalyst is timing-related (launches approaching) rather than a reported earnings beat, implying a modest positive read-through for the stock.

Analysis

Morgan Stanley says Merck is positioned to gain share as its pipeline drugs near commercialization, supporting a more favorable near-term outlook. The catalyst is timing-related (launches approaching) rather than a reported earnings beat, implying a modest positive read-through for the stock.